Hi Tech Pharmacal
The 10-second takeaway
For the quarter ended Jan. 31 (Q3), Hi Tech Pharmacal beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly. GAAP earnings per share dropped significantly.
Margins contracted across the board.
Hi Tech Pharmacal reported revenue of $64.3 million. The four analysts polled by S&P Capital IQ hoped for revenue of $60.5 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $55.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.43. The four earnings estimates compiled by S&P Capital IQ averaged $0.71 per share. GAAP EPS of $0.43 for Q3 were 46% lower than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 51.1%, 420 basis points worse than the prior-year quarter. Operating margin was 13.6%, much worse than the prior-year quarter. Net margin was 9.2%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $65.8 million. On the bottom line, the average EPS estimate is $0.80.
Next year's average estimate for revenue is $238.0 million. The average EPS estimate is $2.39.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 205 members out of 221 rating the stock outperform, and 16 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give Hi Tech Pharmacal a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $39.00.
- Add Hi Tech Pharmacal to My Watchlist.